282+ total transactions representing $121 billion in aggregate value — 15 tracked below spanning 2016–2026 · 2 industries
MTS served as exclusive financial advisor to Neurocrine Biosciences on the divestiture of its European commercial business (Neurocrine Group Limited) to Immedica Pharma.
MTS served as financial advisor to Taiho Pharmaceutical on its acquisition of Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates.
MTS Health Partners is acting as Immedica's exclusive financial advisor in connection with the acquisition of Marinus Pharmaceuticals.
MTS served as exclusive financial advisor to BioLineRx on exclusive license agreement with Ayrmid Ltd.
MTS Health Partners provided financial advice to Seagen alongside Centerview Partners on Pfizer's $43 billion acquisition. One of the largest biopharma M&A deals in history.
MTS Health Partners acted as financial advisor to EQRx alongside Goldman Sachs on Revolution Medicines' all-stock acquisition.
MTS served as exclusive financial advisor to DispatchHealth in the sale of its Mobile Imaging business to TridentCare.
MTS served as exclusive financial advisor to Alma on its sale to Spring Health.
MTS served as financial advisor to DispatchHealth on its merger with Medically Home, creating the nation's most comprehensive high-acuity care-at-home platform.
MTS Health Partners acted as financial advisor to Truepill on its acquisition by LetsGetChecked.
MTS and Houlihan Lokey acted as financial advisors to the Special Committee on Sharecare's take-private acquisition by Altaris for $1.43 per share in cash.
MTS Health Partners acted as exclusive financial advisor to SMV Property Holdings in connection with an $835 million refinancing.
MTS served as financial advisor to PathGroup and its shareholders on recapitalization with Pritzker Group Private Capital and Primus Capital.